# Immunocore

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunocore

- Industry: Biotechnology
- Headquarters: Abingdon, UK
- Website: www.immunocore.com
- Total disclosed funding: $140M
- Latest round: Series C (Dec 21, 2020)
- Investors on record: 10

## About

Immunocore, Ltd., headquartered in Abingdon, UK, is a biotechnology company focused on developing innovative immunotherapeutic products that enhance the immune system's ability to target and eliminate diseased cells.Immunocore, Ltd. specializes in the development of immunotherapeutic products. Founded in 2008 in Abingdon, UK, it has undergone strategic pivots to enhance its focus on T cell receptor technology. The company raised USD 140.00 mn in a PIPE funding round on February 4, 2021, attracting investments from General Atlantic, RTW Investments, and Rock Springs Capital, totaling USD 140.00 mn raised to date. The CEO is Bahija Jallal.Immunocore Holdings plc develops innovative immunotherapeutic products that improve the immune system's ability to target and remove diseased cells. The core technology, ImmTAX, modifies T cell receptors to recognize and destroy tumor or infected cells while minimizing autoimmune responses. Their bispecific T cell receptor therapies address various conditions, including solid tumors, infectious diseases, and autoimmune disorders, serving healthcare professionals and researchers across North America, Europe, and Asia.In the most recent year of 2023, Immunocore reported a revenue of USD 297.50 mn, with an EBITDA of USD 24.71 mn. The company's revenue comes primarily from partnerships with biopharmaceutical companies, healthcare providers, and research institutions through collaborations and licensing agreements, facilitating the development and commercialization of its therapies.Immunocore aims to expand its market presence by launching new bispecific T cell receptor therapies while targeting additional markets across North America, Europe, and Asia. The recent funding raised in February 2021 will support these initiatives and is expected to bolster their research and development efforts. The company plans to leverage its financial resources to enhance its operational capabilities and accelerate the delivery of its innovative therapies to the market.

## Funding rounds

- Series C, Dec 21, 2020, $76M — General Atlantic, BlackRock, RTW Investments, Rock Springs Capital
- Series B, Mar 2, 2020, $64M — General Atlantic, CCB International, Bill & Melinda Gates Foundation, Eli Lilly & Company, RTW Investments, Rock Springs Capital, JDRF T1D Fund, Terra Magnum Capital Partners, Wuxi AppTec Group

## Investors

- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series B, Series C
- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series B
- Bill & Melinda Gates Foundation — Series B
- Eli Lilly & Company — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B, Series C
- Rock Springs Capital — Series B, Series C
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series B
- Terra Magnum Capital Partners (https://capitalatlas.ai/funds/terra-magnum-capital-partners) — Series B
- Wuxi AppTec Group — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C